Physicians and pharmacists may only
engage in Collaborative Drug Therapy Management when:
(a) An Agreement has been appropriately
executed and a written attestation has been filed with and approved by the
Board of Pharmacy and the Board of Medical Examiners; and
(b) The patient or the patient's authorized
representative has signed an Agreement-specific consent that the patient is to
receive services from a healthcare team, including a Collaborating
patient's consent to treatment under a Collaborative Drug Therapy Management
Agreement shall be made part of the patient record.
(3) The written attestation shall include the
names of the Collaborating Pharmacist, Collaborating Physician, and any
Covering Physician or Covering Pharmacist, if applicable, participating in the
Agreement, the date of the Agreement, and a description of the scope of the
services covered by the Agreement.
(4) The written attestation shall include a
formulary and a list of services authorized by the Agreement.
(5) The Agreement and written attestation
must be provided to the Board of Pharmacy and the Board of Medical Examiners no
later than ten (10) days after the Agreement is signed by the
(6) A copy of the
Agreement, including any addendum, modification, or termination shall be
accessible at each practice site and shall be made available to the Board of
Pharmacy and Board of Medical Examiners for review upon request.
Ala. Admin. Code r.
Administrative Monthly Volume XXXIX, Issue No. 11, August 31,
2021, eff. 10/15/2021.
Author: Alabama Board of Medical
Code of Ala.
Act 2019-368 (Code of Ala. 1975, §